Revenue
Margin
Demand
Guidance
Tone
Metrics cut 1
- Rajasthan FY27 revenue guidance lowered to ₹100-150 crores (conservative) (from ₹200-250 crores prior)
Event Participants
Executives
3 Mitesh Dave, Yash Mutha, Chandra Prakash Singh
Analysts
7 Lokesh Manik, Pooja Sanghvi, Rajat, Raman, Surya Patra, Vivek Kumar, Unidentified Participant
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹2,355 million | +22% YoY from ₹1,930 million; like-to-like projects grew ~12%, demonstrating organic growth beyond new project wins |
| Retail Revenue | ₹193 million | +64% YoY from ₹118 million; ~8-9% of group revenue, driven by expanded 4,000+ touchpoint network |
| Rajasthan Revenue | ₹26 crores | First full quarter of operations; management expects doubling in Q2, full year ₹100-150 crores conservative target |
| EBITDA | ₹588 million | Margin 25% vs 27% YoY; compression due to ~4,000 manpower onboarded in Rajasthan and logistics costs ahead of revenue realization |
| PAT | ₹166 million | 7% margin; reflects front-ended project costs against ramp-up phase |
| Radiology:Pathology Mix | 41:59 | Shifted toward pathology due to Rajasthan ramp-up; MRI centers operationalized in staggered manner impacting radiology contribution |
| Accredited Centers | 124 | Added 12 NABH accreditations in Q1; includes NABL, KAP and ACR |
| Retail Touchpoints | 4,000+ | Expanded across 7 states via franchisee model, Kiosks (KBC), Refill Centers (KRC) and strategic alliances |
Geographic & Segment Commentary
- Rajasthan PPP: Moved decisively into go-live phase with 31 mother labs, 62 hub labs and 1,228 collection centers operational. This infrastructure is expected to unlock operating leverage as volumes ramp; upfront costs of ~4,000 manpower were largely absorbed within Q1, with revenue expected to double in Q2.
- Radiology/MRI: 8 of 17 MRI centers in Maharashtra were inaugurated and operationalized during the quarter; remaining centers to go live by end of Q3. Existing radiology projects completed tenure in the quarter causing some drag, but like-to-like growth of ~12% indicates healthy core expansion.
- Retail (RPL): Revenue grew 64% YoY to ₹193 million with touchpoints surpassing 4,000 across 7 states. Business is EBITDA-negative in Q1 but drag has narrowed substantially; management targets EBITDA positivity by Q2 FY27 and 10-15% of group revenue contribution by year-end.
Company-Specific & Strategic Commentary
- Himachal Pradesh Expansion: Awarded CT project for 34 CT scans across the state, expanding from original 12 centers; predominantly cash-paying model. Extends revenue visibility in the state for 10+ years and Krsnaa's presence to ~25 years total.
- Insurance-linked Diagnostics Product: First-of-its-kind proposition combining preventive diagnostics with financial protection to be launched shortly; expected to create new consumer engagement dimension.
- Hospital Partnership Model: Apulki Hospital Pune commenced operations with exclusive diagnostic rights for radiology and pathology including super-specialty segments; platform for 30+ year relationship across Apulki hospitals.
- Technology & AI Adoption: Expanding AI usage across consumer engagement, Excel reporting and business analytics to improve operational efficiency.
- Promoter Warrant Infusion: Funds raised via promoter warrants for capital expenditure on projects and potential acquisitions.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Rajasthan Revenue FY27 | ₹100-150 crores (conservative), aspiration ₹200-250 crores | Q1 revenue of ₹26 crores expected to double in Q2; clear visibility on stated conservative range with upside optionality |
| Retail EBITDA | Positive by Q2 FY27 | Drag has narrowed substantially from previous quarters; network scale and utilization expected to drive breakeven |
| Retail Revenue Mix | 10-15% of group revenue by FY27 end | Current ~9%; driven by network expansion and wellness/illness package uptake |
| Consolidated EBITDA Margin | Return to double digits by year-end | Dependent on Rajasthan normalization and RPL turning positive; like-to-like business margins stable |
| Rajasthan MRI Centers | All 17 operational by end of Q3 FY27 | 8 already live in Maharashtra; balance in progress |
| Himachal CT Project | Revenue/investment details to be shared in coming quarters | Discussions ongoing; cash-paying project with 10-year visibility |
Risks & Constraints
| Risk | Context |
|---|---|
| Government Receivables | Himachal Pradesh funds flowing after approval; Karnataka delayed due to procedural changes following ministry change; Maharashtra also pending. Management expects Karnataka collections by Q2, but 3 states remain behind schedule. |
| Margin Compression from Ramp-up | Front-ended capex model means fixed costs (labs, manpower, logistics) borne before revenue scales; EBITDA margin compressed to 25% from 27%. Like-to-like business margins stable, but overall profitability depends on Rajasthan and MRI utilization ramp-up pace. |
| Concentration in PPP Tenders | Many contracts have fixed tender rates; CGHS rate revisions not applicable to current contracts. Future benchmarked tenders provide upside but current revenue tied to negotiated rates. |
| Competitive Retail Landscape | Building consumer trust in tier 2/3 markets against established doctor-referral models; Krsnaa differentiates on quality accreditations (124), reach and pricing rather than commissions. |
Q&A Highlights
Fees to Hospital Increase
- Question: Fee to hospital expense jumped to ₹41 crores sequentially and YoY - what explains this? (Raman)
- Answer: The accounting line includes partner revenue share for Rajasthan and Manipur projects where local partners handle certain operations and manpower. Nomenclature is misleading - this is essentially partner expense for statewide deployment operations. (Yash Mutha)
Rajasthan Revenue Trajectory
- Question: Was earlier guidance of ₹200-250 crores from Rajasthan FY27 intact given the conservative ₹100-150 crores shared? (Raman)
- Answer: Conservative guidance is ₹100-150 crores with clear visibility; aspiration remains ₹200-250 crores. Q2 revenue expected to double as labs/centers ramp. What might look like lower guidance reflects conservatism rather than target change. (Yash Mutha, Mitesh Dave)
Retail EBITDA and Recovery
- Question: Is RPL still negative at EBITDA and what's the absolute drag? (Surya Patra)
- Answer: Retail is EBITDA-negative in Q1 due to ground deployment costs across 5 states, but loss has narrowed significantly from prior quarters. Target is EBITDA positive by Q2 FY27. Once breakeven achieved, the journey is upward. (Yash Mutha, Mitesh Dave)
Volume vs Value Growth Drivers
- Question: What drove volume growth versus value growth this quarter? (Pooja Sanghvi)
- Answer: Volume growth from new infrastructure - Rajasthan pathology and added MRI centers; like-to-like also contributed from efficiency initiatives. Value growth driven by new footfalls, repeat cycles, and retail adoption. (Mitesh Dave)
Receivables Recovery Status
- Question: When can we expect recovery from Himachal and Karnataka? (Pooja Sanghvi)
- Answer: Himachal funds allocated and flowing. Karnataka conversations ongoing, delayed by procedural changes post ministry transition; expect collections by Q2. HP, Karnataka and Maharashtra are the three states where teams are working to recover government dues; all others on track. (Yash Mutha)
Retail Trust Building in Tier 2/3
- Question: How are you winning customers in tier 2-3 given doctor referral dynamics and existing diagnostic partnerships? (Vivek Kumar)
- Answer: Krsnaa leverages track record - 3 crore patients served, 124 accreditations (highest among peers) - to educate doctors on quality and pricing; doesn't pay commissions. PPP operations have already built trust with 30,000+ doctors whose reports are seen and prescribed upon in government hospitals. Retail model rides this existing ecosystem with structurally lower customer acquisition costs. (Yash Mutha, Mitesh Dave)
Employee Expense Rationalization
- Question: Employee cost appears flat YoY despite Rajasthan ramp-up - will hiring increase? (Rajat)
- Answer: Most manpower came toward end of Q1; some employees sit under partner/business associate line (fees to hospital). Management rationalized headcount and expects future hiring in tandem with revenue growth - if revenue doubles, manpower impact won't be significant. (Yash Mutha)
CGHS Rate Benefit
- Question: Have you seen CGHS rate revisions impact this quarter like peers? (Surya Patra)
- Answer: Contractual rates under current tenders remain as per tender terms; CGHS change doesn't reflect immediately. Benefits will accrue in forthcoming tenders benchmarked to new rates. (Yash Mutha)
Key Takeaway
Krsnaa Diagnostics reported 22% YoY revenue growth in Q1 FY27 to ₹2,355 million, driven by Rajasthan PPP (₹26 crores in first operational quarter) and 64% retail growth, with like-to-like projects expanding ~12%. EBITDA margin compressed 200 bps YoY to 25% from front-loaded costs of ~4,000 manpower and logistics infrastructure; PAT stood at ₹166 million (7% margin). Management guided for Rajasthan revenue doubling in Q2, RPL reaching EBITDA positivity by Q2, retail reaching 10-15% of revenue by FY27 end, and overall margins returning to double digits by year-end. Strategic milestones include the Himachal Pradesh 34-CT award, 8 operationalized MRI centers of 17, 4,000+ retail touchpoints, and Apulki Hospital partnership for long-duration exclusive rights. Key watch points are government receivables from Himachal, Karnataka and Maharashtra (expected recovery by Q2) and disciplined execution of the infrastructure-to-revenue conversion phase across recently commissioned projects.
Transcript incomplete - specific balance sheet metrics (working capital, capex details) and detailed segment-wise asset quality metrics not fully available in the transcript for summary.